Abstract
The vascular endothelial growth factor (VEGF) plays a key role in the development of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME), resulting in a significant visual loss among patients with diabetes mellitus. Systemic VEGF-A and the interplay between membrane-bound VEGF receptors and VEGF-R1 (soluble form) are key to angiogenesis and vasculogenesis. Furthermore, patients with diabetes have a higher risk of hypertension and proteinuria, two surrogate markers of systemic VEGF inhibition. Pegaptanib, ranibizumab, bevacizumab and roboxistaurin are the currently available anti-VEGF agents. Agents with activity occurring later down the angiogenic pathway and those drugs with potential to synergize with anti-VEGF-A technologies are being developed. In recent years, inhibition of ocular VEGF has emerged as a promising treatment modality for diabetes and is currently undergoing evaluation in clinical trials. A potential role for these anti-VEGF agents in the prevention of PDR and DME are also emerging.
Keywords: Diabetic retinopathy, vascular endothelial growth factor, anti-VEGF, pegaptanib, ranibizumab, bevacizumab, roboxistaurin, diabetic macular edema
Current Pharmaceutical Biotechnology
Title: Anti-Angiogenesis Drugs in Diabetic Retinopathy
Volume: 12 Issue: 3
Author(s): V. Swetha E. Jeganathan
Affiliation:
Keywords: Diabetic retinopathy, vascular endothelial growth factor, anti-VEGF, pegaptanib, ranibizumab, bevacizumab, roboxistaurin, diabetic macular edema
Abstract: The vascular endothelial growth factor (VEGF) plays a key role in the development of proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME), resulting in a significant visual loss among patients with diabetes mellitus. Systemic VEGF-A and the interplay between membrane-bound VEGF receptors and VEGF-R1 (soluble form) are key to angiogenesis and vasculogenesis. Furthermore, patients with diabetes have a higher risk of hypertension and proteinuria, two surrogate markers of systemic VEGF inhibition. Pegaptanib, ranibizumab, bevacizumab and roboxistaurin are the currently available anti-VEGF agents. Agents with activity occurring later down the angiogenic pathway and those drugs with potential to synergize with anti-VEGF-A technologies are being developed. In recent years, inhibition of ocular VEGF has emerged as a promising treatment modality for diabetes and is currently undergoing evaluation in clinical trials. A potential role for these anti-VEGF agents in the prevention of PDR and DME are also emerging.
Export Options
About this article
Cite this article as:
Swetha E. Jeganathan V., Anti-Angiogenesis Drugs in Diabetic Retinopathy, Current Pharmaceutical Biotechnology 2011; 12 (3) . https://dx.doi.org/10.2174/138920111794480525
DOI https://dx.doi.org/10.2174/138920111794480525 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Adiponectin in Obesity, Hypertension, and Metabolic Syndrome
Current Hypertension Reviews Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Impact of Jugular Vein Valve Function on Cerebral Venous Haemodynamics
Current Neurovascular Research New Insight into Urate-Related Mechanism of Cardiovascular Damage
Current Pharmaceutical Design Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Dyslipidaemia in Rheumatoid Arthritis: The Role of Inflammation, Drugs, Lifestyle and Genetic Factors
Current Vascular Pharmacology The Vectorcardiogram and the Main Dromotropic Disturbances
Current Cardiology Reviews Myocardial Perfusion and Coronary Vasomotor Function: Emerging Role of PET Imaging
Vascular Disease Prevention (Discontinued) Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Development of Floating Multiple Unit Mini Tablets of Bosentan Using QbD: Characterisation and Pharmacokinetic Study
Drug Delivery Letters Distribution of Left Ventricular Thrombus among Patients with Significantly Impaired Systolic Function
New Emirates Medical Journal Exploiting High-Throughput Ion Channel Screening Technologies in Integrated Drug Discovery
Current Pharmaceutical Design Diagnosis of Gout: Considering Clinical and Research Settings
Current Rheumatology Reviews The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Novel Hypotensive Agents from Verbesina Caracasana: Structure, Synthesis and Pharmacology
Current Medicinal Chemistry Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design New Insights into the Mechanisms Underlying Vascular and Cardiac Effects of Urocortin
Current Vascular Pharmacology Epidemiological Aspects of Stroke in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets